Bristol Myers Squibb (BMY) Total Current Liabilities (2009 - 2026)
Bristol Myers Squibb's (BMY) quarterly Total Current Liabilities came in at $18.7 billion in Q2 2026, down 32.22% year-over-year from $27.5 billion in Q2 2025, and down 2.6% quarter-over-quarter from $19.2 billion in Q1 2026.
Analysis
Bristol Myers Squibb (BMY) Total Current Liabilities (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (BMY) has reported Total Current Liabilities for 18 consecutive years, with $18.7 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Current Liabilities fell 32.22% year-over-year to $18.7 billion in Q2 2026; TTM through Jun 2026 was $18.7 billion, a 32.22% decrease from a year earlier, with the FY2025 full-year figure at $23.4 billion, down 1.5% from the prior year.
- Total Current Liabilities was $18.7 billion for Q2 2026 at Bristol Myers Squibb, down from $19.2 billion in the prior quarter.
- Over five years, Total Current Liabilities peaked at $28.1 billion in Q3 2025 and troughed at $18.7 billion in Q2 2026.
- A 5-year average of $22.6 billion and a median of $22.7 billion in 2022 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities surged 35.3% in 2024 and plunged 32.22% in 2026, its largest moves.
- Over 5 years, Total Current Liabilities stood at $21.9 billion in 2022, then advanced by 1.7% to $22.3 billion in 2023, then rose by 6.79% to $23.8 billion in 2024, then fell by 1.5% to $23.4 billion in 2025, then dropped by 20.32% to $18.7 billion in 2026.
- The last three Total Current Liabilities figures came in at $18.7 billion (Q2 2026), $19.2 billion (Q1 2026), and $23.4 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 32.65 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 18.66 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 37.11 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | 354.06 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 2.12 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 1.31 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.66 Bn |
| Mar 31, 2026 | 19.16 Bn |
| Dec 31, 2025 | 23.42 Bn |
| Sep 30, 2025 | 28.14 Bn |
| Jun 30, 2025 | 27.53 Bn |
| Mar 31, 2025 | 24.07 Bn |
| Dec 31, 2024 | 23.77 Bn |
| Sep 30, 2024 | 22.64 Bn |
| Jun 30, 2024 | 23.27 Bn |
| Mar 31, 2024 | 25.82 Bn |
| Dec 31, 2023 | 22.26 Bn |
| Sep 30, 2023 | 23.46 Bn |
| Jun 30, 2023 | 20.15 Bn |
| Mar 31, 2023 | 19.09 Bn |
| Dec 31, 2022 | 21.89 Bn |
| Sep 30, 2022 | 18.93 Bn |
| Jun 30, 2022 | 20.92 Bn |
| Mar 31, 2022 | 22.82 Bn |
| Dec 31, 2021 | 21.87 Bn |
| Sep 30, 2021 | 21.46 Bn |